Propanc Biopharma Secures Provisional Patent for Synthetic Cancer Therapy Production
Event summary
- Propanc Biopharma filed a provisional patent application with IP Australia for methods of producing trypsinogen and chymotrypsinogen.
- The patent covers an optimized expression system for Rec-PRP, a fully synthetic recombinant version of PRP, intended as a long-term cancer therapy.
- The global metastatic cancer market is projected to reach $111 billion by 2027, according to Emergen Research.
- This is the third patent application filed by Propanc in the past two months.
- The synthetic version aims to improve stability, global distribution (especially in warmer climates), and consistency of production.
The big picture
Propanc's focus on a fully synthetic version of PRP represents a potential shift in cancer therapy development, moving away from reliance on in vivo expression systems. This approach addresses significant logistical challenges associated with current therapies, particularly in global distribution. The company's valuation will be heavily influenced by the success of its patent filings and the eventual clinical and commercial viability of Rec-PRP within the massive, but competitive, metastatic cancer treatment market.
What we're watching
- Regulatory Approval
- The shift to a fully synthetic production method could streamline regulatory pathways, but the company will need to demonstrate efficacy and safety to secure approval for Rec-PRP.
- Commercialization
- The ability to produce Rec-PRP without refrigeration will be critical for global distribution and adoption, particularly in developing markets, and will need to be validated at scale.
- IP Portfolio
- The success of Propanc's strategy hinges on the ability to secure and defend these patents, as competitors may attempt to develop similar synthetic production methods.
Related topics